Investigating Fulgent Genetics, Inc.
Pomerantz LLP is currently investigating claims concerning Fulgent Genetics, Inc. (NASDAQ: FLGT). The firm aims to provide representation for investors who may be affected by potential securities fraud or unethical business practices associated with Fulgent.
What Prompted the Investigation?
The investigation stems from disclosures made by Fulgent about receiving a civil investigative demand from the U.S. Department of Justice. This demand pertains to potentially false claims that may have been submitted under the Uninsured Program, highlighting serious concerns about the company’s compliance with legal norms.
Market Impact
On the heels of this announcement, the market reacted negatively, causing Fulgent’s stock price to decrease significantly. Specifically, the share price fell by $0.41, equating to a 2.61% drop, closing at $15.28 shortly afterwards. Such movements reflect investors' reactions to significant company news that may signify underlying issues.
About Pomerantz LLP
Pomerantz LLP has a well-established reputation as a leading firm specializing in corporate, securities, and antitrust class litigation. With multiple offices across key cities, this firm has pioneered the domain of securities class actions for over 85 years, advocating fiercely for the rights of those impacted by corporate misconduct.
Continuing the Legacy
The firm was founded by Abraham L. Pomerantz, often regarded as a visionary in the class action space. His work laid the foundation for the current efforts of Pomerantz LLP, driving forward initiatives aimed at securing justice and compensation for investors who have suffered due to corporate violations.
Recognizing the Importance of Accountability
The serious nature of the investigation presents a vital opportunity for account and justice for investors who may have faced losses due to inadequate disclosures from Fulgent. Investors are encouraged to stay informed and engaged as developments unfold.
How to Get Involved
Interested parties are encouraged to connect with Pomerantz LLP for further information on how to join the ongoing class action lawsuit. This initiative represents a crucial moment for stakeholders to seek redress and support during a turbulent time for Fulgent Genetics.
Frequently Asked Questions
What is the current situation regarding Fulgent Genetics?
Fulgent Genetics is facing an investigation led by Pomerantz LLP concerning potential securities fraud and wrongful business conduct.
Who is leading the investigation?
The investigation is being conducted by Pomerantz LLP, a firm recognized for its expertise in class action litigation.
What happened to Fulgent's stock price recently?
Following the news of the investigation, Fulgent's stock fell by 2.61%, reflecting investor concerns over the company's legal challenges.
Why should investors be concerned?
Investors should be concerned as the investigation could reveal serious compliance issues, which might impact Fulgent’s market integrity and financial stability.
How can investors get in touch with Pomerantz LLP?
Investors looking to join the class action can reach out to Pomerantz LLP, specifically contacting Danielle Peyton for detailed guidance.
